Infant Immunologic and Neurologic Development following Maternal Infection in Pregnancy during Recent Epidemics
近期流行病期间妊娠期感染后婴儿的免疫和神经系统发育
基本信息
- 批准号:10784250
- 负责人:
- 金额:$ 37万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-04-24 至 2024-03-31
- 项目状态:已结题
- 来源:
- 关键词:2019-nCoVAddressAffectAgeAmericasAntigensAreaAwarenessBehavioralBiological MarkersBirthBrainBrazilCOVID-19COVID-19 pandemicCephalicChildChild WelfareChildhoodClinicalCognitionCollaborationsCommunicable DiseasesDataDevelopmentDiagnosisDiagnosticDiscipline of obstetricsDiseaseDisease-Free SurvivalEnrollmentEpidemicEpidemiologyEvaluationExposure toFetusFunctional disorderFutureGoalsGrowthHealthImageImmuneImmune responseImmune systemImmunizationImmunoglobulin MImmunologicsImmunologyImpairmentInfantInfectionInflammatoryInfrastructureKnowledgeLanguageLanguage DelaysLanguage DevelopmentLearningLearning DisabilitiesLiteratureLongitudinal cohortLongitudinal cohort studyMaternal-Fetal TransmissionMaternally-Acquired ImmunityMethodsMolecularMonitorMothersMotorNeurocognitive DeficitNeurologicNeuropathogenesisOrganOutcomePathogenesisPatient RecruitmentsPerinatal InfectionPersonal SatisfactionPopulationPregnancyPregnancy TrimestersPregnant WomenProductivityProspective cohortProteomicsReportingResearchResearch PersonnelRiskSARS-CoV-2 infectionSchool-Age PopulationScientistSensorySeveritiesT-LymphocyteTechnologyTimeUnited StatesVaccinesVertical TransmissionViralVirusVulnerable PopulationsZIKAZIKV infectionZika Virusantenatalautism spectrum disordercalcificationchemokineclinical research sitecohortcongenital infectioncongenital zika syndromecoronavirus diseaseearly childhoodexperiencefetalglobal health emergencyhearing impairmentimmune activationimmune functionin uteroinfant outcomematernal outcomemultidisciplinaryneurodevelopmentneurological rehabilitationneurosensoryneutralizing antibodynew outbreaknovelnovel coronaviruspandemic diseasepathogenprenatalprogramsresponsesample collectiontoolvaccine responsevirology
项目摘要
Abstract/Summary
The massive outbreak of newly emerged coronavirus disease 2019 (COVID-19) saw rapid global
spread, leading to a pandemic infection and an unprecedented global health emergency. Just
years before, we witnessed the devastating impact of Zika virus (ZIKV) to unborn fetuses in the
Americas. This proposal responds to the need to fill critical gaps in the understanding of the
clinical repercussions of antenatal infections such as ZIKV and SARS-CoV-2 infection in pregnant
women to the developing immune system of their infants, through the evaluation of cellular and
humoral immune responses and clinical and neurodevelopmental outcomes following maternal
immune activation (MIA) in this vulnerable population. Our team of researchers has been
collaborating over the last 7 years to characterize the clinical and cellular effects of in utero
transmission of Zika virus (ZIKV), with the collection of specimens from over hundreds of mother-
infant pairs from Brazil. We reported on multiple obstetrical and clinical outcomes of infants with
congenital ZIKV infection in the literature, including that ZIKV vertical transmission rate is at least
65%, that infected children do not develop ZIKV specific neutralizing antibodies despite an early
IgM response, and that maternal humoral immune responses tend to be robust with highly
neutralizing activity. During the COVID-19 pandemic we established a cohort of mother-infant
pairs at UCLA and Fiocruz, Rio de Janeiro and controls with mother-infant dyads enrolled to
date in both places. We are utilizing the existing infrastructure and scientific methods developed
in the aftermath of the ZIKV epidemic to further evaluate clinical, cellular humoral and
inflammatory parameters predicting immunologic outcomes in infants and children exposed to
either maternal ZIKV and SARS Cov2 infection. The main goal of the proposed research is to
comprehensively characterize repercussions of MIA on infant immune development and clinical
outcomes, with a focus on immune pathogenesis. We include a longitudinal cohort of 200 mother-
infant pairs with COVID-19 and 100 healthy control mother-infant pairs in the US and Brazil and
200 mother-infant pairs with ZIKV in Brazil and 100 healthy control pairs at the same clinical sites
to address these goals. This RO1 proposes to evaluate the repercussions of MIA on infant well-
being and immune development. State of the art technology is used to address the scientific aims,
with the research led by experts in the field of immunology, infectious diseases & congenital
infections who have ongoing successful, productive partnerships. The data rendered will be
crucial for the knowledge of immune pathogenesis in pediatric populations with antenatal viral
exposures.
摘要/总结
2019 年新型冠状病毒病(COVID-19)在全球范围内迅速爆发
传播,导致大流行感染和前所未有的全球卫生紧急情况。只是
几年前,我们目睹了寨卡病毒(ZIKV)对未出生胎儿的毁灭性影响
美洲。该提案满足了填补理解中的关键空白的需要。
ZIKV 和 SARS-CoV-2 感染等产前感染对孕妇的临床影响
通过评估细胞和免疫系统,妇女可以了解婴儿免疫系统的发育情况
产后体液免疫反应以及临床和神经发育结果
该弱势群体的免疫激活(MIA)。我们的研究团队已经
在过去的 7 年里合作来描述子宫内的临床和细胞效应
寨卡病毒(ZIKV)的传播,从数百名母亲身上收集了样本
来自巴西的婴儿对。我们报告了患有以下疾病的婴儿的多项产科和临床结果:
文献中记载的先天性 ZIKV 感染,其中 ZIKV 垂直传播率至少为
65% 的人认为,尽管早期就出现了 ZIKV 感染,但受感染的儿童并未产生 ZIKV 特异性中和抗体
IgM 反应,并且母体体液免疫反应在高度
中和活性。在 COVID-19 大流行期间,我们建立了一个母婴队列
在加州大学洛杉矶分校和里约热内卢菲奥克鲁兹配对,并与注册的母婴二人组进行对照
两个地方都可以约会。我们正在利用现有的基础设施和开发的科学方法
在 ZIKV 流行后进一步评估临床、细胞体液和
炎症参数可预测暴露于以下环境的婴儿和儿童的免疫结果
母亲 ZIKV 和 SARS Cov2 感染。拟议研究的主要目标是
全面描述 MIA 对婴儿免疫发育和临床的影响
结果,重点是免疫发病机制。我们包括 200 名母亲的纵向队列
美国和巴西的 100 对健康对照母婴对感染了 COVID-19 的婴儿
巴西 200 对感染 ZIKV 的母婴和同一临床地点的 100 对健康对照
来实现这些目标。该 RO1 建议评估 MIA 对婴儿健康的影响
存在和免疫发育。最先进的技术用于实现科学目标,
由免疫学、传染病和先天性疾病领域的专家领导的研究
感染者拥有持续成功、富有成效的伙伴关系。呈现的数据将是
对于了解产前病毒感染儿科人群的免疫发病机制至关重要
曝光。
项目成果
期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Infant movement classification through pressure distribution analysis.
通过压力分布分析对婴儿运动进行分类。
- DOI:
- 发表时间:2023-08-16
- 期刊:
- 影响因子:0
- 作者:Kulvicius, Tomas;Zhang, Dajie;Nielsen;Bölte, Sven;Kraft, Marc;Einspieler, Christa;Poustka, Luise;Wörgötter, Florentin;Marschik, Peter B
- 通讯作者:Marschik, Peter B
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Jae U Jung其他文献
Phospholipase A2 inhibitor and LY6/PLAUR domain-containing protein PINLYP regulates type I interferon innate immunity
磷脂酶A2抑制剂和LY6/PLAUR结构域蛋白PINLYP调节I型干扰素先天免疫
- DOI:
10.1007/978-3-319-40715-9_9 - 发表时间:
2022 - 期刊:
- 影响因子:0
- 作者:
Zhongshun Liu;Congwei Jiang;Zhangmengxue Lei;Sihan Dong;Linlin Kuang;Chenxu Huang;Ying Gao;Mu Liu;Hui Xiao;Patrick Legembre;Jae U Jung;Huaping Liang;Xiaozhen Liang - 通讯作者:
Xiaozhen Liang
SIAH1 modulates antiviral immune responses by targeting deubiquitinase USP19.
SIAH1 通过靶向去泛素酶 USP19 调节抗病毒免疫反应。
- DOI:
10.1002/jmv.29523 - 发表时间:
2024-03-01 - 期刊:
- 影响因子:12.7
- 作者:
A. Weerawardhana;Thilina U B Herath;W. A. Gayan Chathuranga;Tae;Pathum Ekanayaka;Kiramage Chathuranga;Ho;Jae U Jung;Jong - 通讯作者:
Jong
Chloroquine, a FDA-approved Drug, Prevents Zika Virus Infection and Its Associated Congenital Microcephaly in Mice
氯喹是 FDA 批准的药物,可预防小鼠寨卡病毒感染及其相关的先天性小头畸形
- DOI:
- 发表时间:
2017 - 期刊:
- 影响因子:11.1
- 作者:
Chunfeng Li;Xingliang Zhu;Xue Ji;Natalie Quanquin;Yong-Qiang Deng;Min Tian;Roghigy Aliyari;Xiangyang Zuo;Ling Yuan;Shabbir Khan Afridi;Xiao-feng Li;Jae U Jung;Karin Nielsen-Saines;Frank Xiao-feng Qin;Chengfeng Qin;Zhiheng Xu;Genhong Cheng - 通讯作者:
Genhong Cheng
Jae U Jung的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Jae U Jung', 18)}}的其他基金
Reassortment of Bunyavirus in ticks and animal models
蜱和动物模型中布尼亚病毒的重排
- 批准号:
10512873 - 财政年份:2022
- 资助金额:
$ 37万 - 项目类别:
Reassortment of Bunyavirus in ticks and animal models
蜱和动物模型中布尼亚病毒的重排
- 批准号:
10686796 - 财政年份:2022
- 资助金额:
$ 37万 - 项目类别:
Regulation of lymphangiogenesis by KSHV vIRF3
KSHV vIRF3 对淋巴管生成的调节
- 批准号:
10252172 - 财政年份:2020
- 资助金额:
$ 37万 - 项目类别:
Structural analysis and therapeutic nanobody development of KSHV G-protein coupled receptor
KSHV G 蛋白偶联受体的结构分析和治疗性纳米抗体开发
- 批准号:
10030628 - 财政年份:2020
- 资助金额:
$ 37万 - 项目类别:
相似国自然基金
本体驱动的地址数据空间语义建模与地址匹配方法
- 批准号:41901325
- 批准年份:2019
- 资助金额:22.0 万元
- 项目类别:青年科学基金项目
时空序列驱动的神经形态视觉目标识别算法研究
- 批准号:61906126
- 批准年份:2019
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
针对内存攻击对象的内存安全防御技术研究
- 批准号:61802432
- 批准年份:2018
- 资助金额:25.0 万元
- 项目类别:青年科学基金项目
大容量固态硬盘地址映射表优化设计与访存优化研究
- 批准号:61802133
- 批准年份:2018
- 资助金额:23.0 万元
- 项目类别:青年科学基金项目
IP地址驱动的多径路由及流量传输控制研究
- 批准号:61872252
- 批准年份:2018
- 资助金额:64.0 万元
- 项目类别:面上项目
相似海外基金
Mentoring Emerging Researchers at CHLA (MERCH-LA)
指导 CHLA (MERCH-LA) 的新兴研究人员
- 批准号:
10797938 - 财政年份:2023
- 资助金额:
$ 37万 - 项目类别:
Developing RNA Vaccines to Treat Peanut Hypersensitivity
开发治疗花生过敏的 RNA 疫苗
- 批准号:
10570339 - 财政年份:2023
- 资助金额:
$ 37万 - 项目类别:
The role of pathogen-experienced macrophage subsets in mediating lung immunity and heterologous protection
经历病原体的巨噬细胞亚群在介导肺免疫和异源保护中的作用
- 批准号:
10753773 - 财政年份:2023
- 资助金额:
$ 37万 - 项目类别:
Multiplexed detection of cell-free M. Tuberculosis DNA and its drug-resistant variants in blood
血液中无细胞结核分枝杆菌 DNA 及其耐药变异体的多重检测
- 批准号:
10639855 - 财政年份:2023
- 资助金额:
$ 37万 - 项目类别:
IgG and FcR Characterization in Small Animal Models of RespiratoryDisease
呼吸道疾病小动物模型中的 IgG 和 FcR 表征
- 批准号:
10678229 - 财政年份:2023
- 资助金额:
$ 37万 - 项目类别: